About STCC
Explore STCC’s journey and strategic phases, and discover how it fosters national collaboration to advance translational cancer research through its vision and mission.
The Singapore Translational Cancer Consortium (STCC) is Singapore's nationally coordinated cancer research and translation platform, established in 2020 under the Research, Innovation and Enterprise (RIE) 2020 Plan. Registered as a business unit under the Consortium for Clinical Research and Innovation Singapore (CRIS), STCC was founded to unite the nation's cancer research community under a single, cohesive framework, synergising capabilities and raising Singapore's prominence and impact in cancer research, regionally and globally.
Phase 1
In its first phase, STCC laid the groundwork for a national cancer research and translation programme by establishing four integrated platforms: Cancer Cancer Clinical Trials & Investigational Medicine Units; Cancer Databases & Tissue Banks; Translational Research Integration & Support; and Business Intelligence & Development, to bring together leading basic, clinical and translational talent and expertise across the cancer research ecosystem.
A central coordinating office, the Strategic Planning and Development Office, was also established to oversee daily operations, manage resources, track deliverables, and support the consortium’s leadership.
Phase 2
Building on the foundations of Phase 1, STCC's second phase focuses on deepening the cancer research and translation infrastructure and fostering greater cohesion across the research community. STCC aims to accelerate and scale up strategic research by promoting integration and developing national-level capabilities, while growing peaks of translational excellence that are globally competitive and capable of transforming cancer healthcare and creating economic value.
In Phase 2, STCC serves as a single front door for researchers, government and industry, simplifying collaboration and enhancing research outcomes. It plays a dual role of building national cancer resources and driving cooperative multi-centre research initiatives. To further strengthen its capabilities, a fifth platform, the Impact & Population Health, was introduced.
STCC's strategies and focus are aligned with Singapore's RIE2025 Human Health and Potential (HHP) priorities in the areas of precision medicine, early detection, value-based healthcare, therapeutics and diagnostics, talent development, data, research excellence, Innovation & Enterprise ecosystem, and healthcare translation.
Our Vision
Become an international leader in translational research in selected cancers of particular relevance to Asians, with high-impact health and economic value.
Our Mission
To be a catalyst, accelerator & enabler of national cancer research and translation through coordinating and driving cohesiveness in the research community.